Compositions and methods for suppressing msutz
AssigneeTHE UNITED STATES GOVERMENT as represented by the DEPARTMENT OF VETERAN'S AFFAIRS
InventorsBrian Kraemer, Jeanna M. Wheeler, Pamela McMillan, Timothy J. Strovas, Jeremy Baker
Life of this patent
Estimating the term…
Abstract
Disclosed herein are small interfering RNA (siRNA) molecules and their use in methods and pharmaceutical compositions for inhibiting the expression of mammalian suppressor of tauopathy 2. Also, described herein are the use of said siRNA molecules in the treatment of Alzheimer's disease or dementia, and reducing accumulation of phosphorylated and aggregated human tau.
Claims44
A composition comprising a nucleic acid sequence or molecule wherein the nucleic acid comprises or consists of a sequence having at least 90% identity to the sequence set forth in:
- (SEQ ID NO:
- 7)
- UUUUCUGGUUUCUGUGCCACACUCAGU,
- (SEQ ID NO:
- 9)
- UUUUUCUGGUUUCUGUGCCACACUCAG,
- (SEQ ID NO:
- 11)
- GUUUUUCUGGUUUCUGUGCCACACUCA,
- (SEQ ID NO:
- 13)
- AGUUUUUCUGGUUUCUGUGCCACACUC,
- (SEQ ID NO:
- 15)
- AAGUUUUUCUGGUUUCUGUGCCACACU,
- (SEQ ID NO:
- 17)
- GCAGGCCAGUACUUGCAGCGCUCCAAA,
- (SEQ ID NO:
- 19)
- AAGCAGGGAAGUAACGGCAGAGCUGAC.
- (SEQ ID NO:
- 21)
- CAAGCAGGGAAGUAACGGCAGAGCUGA,
- (SEQ ID NO:
- 23)
- ACAAGCAGGGAAGUAACGGCAGAGCUG,
- (SEQ ID NO:
- 25)
- UACAAGCAGGGAAGUAACGGCAGAGCU
- (SEQ ID NO:
- 27)
- UUACAAGCAGGGAAGUAACGGCAGAGC,
- (SEQ ID NO:
- 29)
- CUUACAAGCAGGGAAGUAACGGCAGAG,
- (SEQ ID NO:
- 31)
- UCUUACAAGCAGGGAAGUAACGGCAGA,
- (SEQ ID NO:
- 33)
- UUCUUACAAGCAGGGAAGUAACGGCAG,
- (SEQ ID NO:
- 35)
- CACUCAUCUCAGCGUUAGAAAAGCUACC,
- (SEQ ID NO:
- 37)
- UCUGGUUUCUGUGCCACACUCAGUUCAC,
- (SEQ ID NO:
- 39)
- UACUUGCAGCGCUCCAAAAGUUUUUCUG,
- (SEQ ID NO:
- 41)
- UCCCCAUUUUUACAAGCAGGCCAGUACU,
- (SEQ ID NO:
- 43)
- GAUGGGGUGAUGGUAGGCACACUCAUCC,
- (SEQ ID NO:
- 45)
- UUGGGGAAGGCUUUGCAGGGUGAGAUGG,
- (SEQ ID NO:
- 47)
- AAACAUUUUUCAGCAAAUUUACAAUUGG,
- (SEQ ID NO:
- 49)
- UAUUUACAAUUUGGGUGAACAAACAAAC,
- (SEQ ID NO:
- 51)
- UCUGGUUUAGUACACUUUGCAUCAUAUU,
- (SEQ ID NO:
- 53)
- UACUCACAUGAGUGAAGGGACAAUCUGG,
- (SEQ ID NO:
- 55)
- UUGGAGACAGUACUGGAAUUCUUCUACU,
- (SEQ ID NO:
- 57)
- GUGGUGCUGGUGGUGCAACUGGUUUUGG,
- (SEQ ID NO:
- 59)
- ACGGCAGAGCUGACUACUGGAAGGUGGU,
- (SEQ ID NO:
- 61)
- CCAUCUUCUUACAAGCAGGGAAGUAACGG,
- (SEQ ID NO:
- 63)
- GUUUUGGAUGAUAGAAGGGACAUUCCAU,
- (SEQ ID NO:
- 65)
- UACAUUGAGUGUUAAACCUACAAUGUUU,
- (SEQ ID NO:
- 67)
- GUAGAAUGUGCAGUCCGGUCUUGUACAU,
- (SEQ ID NO:
- 69)
- UGGUGGGACAUUAAUGGUGGGAUGGUAG,
- (SEQ ID NO:
- 71)
- UCGAAUCCAUUUCAAGGCAUGUCGUGGU,
- or
- (SEQ ID NO:
- 73)
- UUAUUCGCUGGUUUGAGGUCGAAUCCAU.
A siRNA molecule wherein the siRNA molecule specifically targets at least one sequence selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 5, SEQ ID NO:
- 77 and SEQ ID NO:
- 78 and reduces expression of mammalian suppressor of tauopathy 2 (MSUT2) gene in a cell, wherein the siRNA molecule comprises a 25- to 28-nucleotide blunt-ended double-stranded structure, wherein the siRNA molecule comprises at least one sequence having at least 90% sequence identity selected from the group consisting of SEQ ID NO:
- 6 to SEQ ID NO:
- 73.
A pharmaceutical composition, wherein the composition comprises at least one siRNA molecule according to any of the preceding claims.
A method of treating Alzheimer's disease or dementia, the method comprising:
- administering to a subject with Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule or a composition comprising the siRNA molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 5, SEQ ID NO:
- 77 and SEQ ID NO:
- 78, wherein the siRNA molecule comprises a 25- to 28-nucleotide blunt-ended double-stranded structure, wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:
- 6 to SEQ ID NO:
- 73, and wherein the therapeutically effective amount reduces accumulation of phosphorylated and aggregated human tau.
A method of inhibiting expression of a MSUT2 polynucleotide in a subject, the method comprising administering to a subject with Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule or a composition comprising the siRNA molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 5, SEQ ID NO:
- 77 and SEQ ID NO:
- 78, wherein the siRNA molecule comprises a 25- to 28-nucleotide blunt-ended double-stranded structure, wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:
- 6 to SEQ ID NO:
- 73.
A method of reducing phosphorylated and aggregated human tau protein in a subject, the method comprising administering to a subject with Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule or a composition comprising the siRNA molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 5, SEQ ID NO:
- 77 and SEQ ID NO:
- 78, wherein the siRNA molecule comprises a 25- to 28-nucleotide blunt-ended double-stranded structure, wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:
- 6 to SEQ ID NO:
- 73.
A method of suppressing expression of a MSUT2 polynucleotide in a subject, the method comprising administering to a subject with Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule or a composition comprising the siRNA molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 5, SEQ ID NO:
- 77 and SEQ ID NO:
- 78, wherein the siRNA molecule comprises a 25- to 28-nucleotide blunt-ended double-stranded structure, wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:
- 6 to SEQ ID NO:
- 73.
A method of potentiating a neuroinflammatory response to a pathological tau protein in a subject, the method comprising administering to a subject with Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule or a composition comprising the siRNA molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 5, SEQ ID NO:
- 77 and SEQ ID NO:
- 78, wherein the siRNA molecule comprises a 25- to 28-nucleotide blunt-ended double-stranded structure, wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:
- 6 to SEQ ID NO:
- 73.
A method of decreasing astrocytosis or microgliosis in a subject, the method comprising administering to a subject with Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule or a composition comprising the siRNA molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 5, SEQ ID NO:
- 77 and SEQ ID NO:
- 78, wherein the siRNA molecule comprises a 25- to 28-nucleotide blunt-ended double-stranded structure, wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:
- 6 to SEQ ID NO:
- 73.
A method of reducing neuroinflammation in a subject, the method comprising administering to a subject with Alzheimer's disease or dementia a therapeutically effective amount of a small interfering RNA (siRNA) molecule or a composition comprising the siRNA molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 5, SEQ ID NO:
- 77 and SEQ ID NO:
- 78, wherein the siRNA molecule comprises a 25- to 28-nucleotide blunt-ended double-stranded structure, wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:
- 6 to SEQ ID NO:
- 73.
A method of inhibiting expression of a MSUT2 polynucleotide, the method comprising contacting a cell with a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 5, SEQ ID NO:
- 77 and SEQ ID NO:
- 78, wherein the siRNA molecule comprises a 25- to 28-nucleotide blunt-ended double-stranded structure, wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:
- 6 to SEQ ID NO:
- 73, wherein the siRNA molecule reduces accumulation of phosphorylated and aggregated tau.
A method of suppressing expression of a MSUT2 polynucleotide, the method comprising contacting a cell with a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 5, SEQ ID NO:
- 77 and SEQ ID NO:
- 78, wherein the siRNA molecule comprises a 25- to 28-nucleotide blunt-ended double-stranded structure, wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:
- 6 to SEQ ID NO:
- 73, wherein the siRNA molecule reduces accumulation of phosphorylated and aggregated tau.
A method of potentiating a neuroinflammatory response to a pathological tau protein, the method comprising contacting a cell with a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 5, SEQ ID NO:
- 77 and SEQ ID NO:
- 78, wherein the siRNA molecule comprises a 25- to 28-nucleotide blunt-ended double-stranded structure, wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:
- 6 to SEQ ID NO:
- 73, wherein the siRNA molecule reduces accumulation of phosphorylated and aggregated tau.
A method of decreasing astrocytosis or microgliosis, the method comprising contacting a cell with a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 5, SEQ ID NO:
- 77 and SEQ ID NO:
- 78, wherein the siRNA molecule comprises a 25- to 28-nucleotide blunt-ended double-stranded structure, wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:
- 6 to SEQ ID NO:
- 73, wherein the siRNA molecule reduces accumulation of phosphorylated and aggregated tau.
A method of reducing neuroinflammation, the method comprising contacting a cell with a small interfering RNA (siRNA) molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO:
- 1 to SEQ ID NO:
- 5, SEQ ID NO:
- 77 and SEQ ID NO:
- 78, wherein the siRNA molecule comprises a 25- to 28-nucleotide blunt-ended double-stranded structure, wherein the siRNA molecule comprises at least one sequence selected from the group consisting of SEQ ID NO:
- 6 to SEQ ID NO:
- 73, wherein the siRNA molecule reduces accumulation of phosphorylated and aggregated tau.
The method of any of the preceding claims, wherein the siRNA molecule comprises or consists of a sense strand which comprises or consists of at least one sequence selected from the group of SEQ ID NO:
- 6, SEQ ID NO:
- 8, SEQ ID NO:
- 10, SEQ ID NO:
- 12, SEQ ID NO:
- 14, SEQ ID NO:
- 16, SEQ ID NO:
- 18, SEQ ID NO:
- 20, SEQ ID NO:
- 22, SEQ ID NO:
- 24, SEQ ID NO:
- 26, SEQ ID NO:
- 28, SEQ ID NO:
- 30, SEQ ID NO:
- 32, SEQ ID NO:
- 34, SEQ ID NO:
- 36, SEQ ID NO:
- 38, SEQ ID NO:
- 40, SEQ ID NO:
- 42, SEQ ID NO:
- 44, SEQ ID NO:
- 46, SEQ ID NO:
- 48, SEQ ID NO:
- 50, SEQ ID NO:
- 52, SEQ ID NO:
- 54, SEQ ID NO:
- 56, SEQ ID NO:
- 58, SEQ ID NO:
- 60, SEQ ID NO:
- 62, SEQ ID NO:
- 64 SEQ ID NO:
- 66, SEQ ID NO:
- 68, SEQ ID NO:
- 70, and SEQ ID NO:
- 72;
- and an antisense strand which is complementary to the sense strand which is selected from the group of SEQ ID NO:
- 7, SEQ ID NO:
- 9, SEQ ID NO:
- 11, SEQ ID NO:
- 13, SEQ ID NO:
- 15, SEQ ID NO:
- 17, SEQ ID NO:
- 19, SEQ ID NO:
- 21, SEQ ID NO:
- 23, SEQ ID NO:
- 25, SEQ ID NO:
- 27, SEQ ID NO:
- 29, SEQ ID NO:
- 31, SEQ ID NO:
- 33, SEQ ID NO:
- 35, SEQ ID NO:
- 37, SEQ ID NO:
- 39, SEQ ID NO:
- 41, SEQ ID NO:
- 43, SEQ ID NO:
- 45, SEQ ID NO:
- 47, SEQ ID NO:
- 49, SEQ ID NO:
- 51, SEQ ID NO:
- 53, SEQ ID NO:
- 55, SEQ ID NO:
- 57, SEQ ID NO:
- 59, SEQ ID NO:
- 61, SEQ ID NO:
- 63, SEQ ID NO:
- 65 SEQ ID NO:
- 67, SEQ ID NO:
- 69, SEQ ID NO:
- 71, and SEQ ID NO:
- 73.
Dependencies are inferred from the claim text.